SIRT1 Downregulation by Advanced Glycation End Products Activates RANKL-Dependent Osteoclast Signaling and Drives Chondrocyte Senescence During Osteoarthritis Development
Multi-omics analysis reveals how cellular aging and sugar damage trigger bone loss in osteoarthritis, pinpointing a potential intervention pathway.
Using multi-omics + ML-assisted network analysis, proteomic and transcriptomic integration, and in vivo validation, this study identifies SIRT1 downregulation by advanced glycation end products (AGEs) as a central mechanism linking metabolic aging to osteoclast activation and chondrocyte senescence in osteoarthritis. The AGE-RAGE-SIRT1-RANKL axis is proposed as a targetable pathway for age-related OA progression.
What the study was
- Study design
- In vitro + in vivo mouse model study with human tissue data integration
- Population
- Mouse OA model + human tissue samples from OA patients; Inner Mongolia
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Aging Cell
Why it surfaced
Aging-related joint disease mechanism with therapeutic target implications; integrates multi-omics and ML in aging tissue research. Capped by preclinical study design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.